<DOC>
	<DOC>NCT00654485</DOC>
	<brief_summary>The purpose of this study is to compare the efficacy of treatment with rosuvastatin with atorvastatin in reducing Low density lipoprotein cholesterol over 6 weeks of treatment in subjects with metabolic syndrome.</brief_summary>
	<brief_title>COMETS - Compare the Efficacy of Rosuvastatin With Atorvastatin and Placebo in the Treatment of Non-Diabetic, Non-Atheroscleric, Metabolic Syndrome Subjects</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Presence of 3 or more coronary heart disease risk factors as defined by the protocol. Fasting low density lipoprotein cholesterol level of &gt; 130 mg/dL. Documented history of, or high risk of coronary heart disease or other established atherosclerotic disease. Not previously taken statins. The use of lipid lowering drugs or dietary supplements after Visit 1 Active arterial disease eg Unstable angina, or recent arterial surgery Blood lipid levels above the limits defined in the protocol Uncontrolled hypertension, hypothyroidism, alcohol or drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Cholesterol</keyword>
	<keyword>hypercholesterolemia</keyword>
	<keyword>low density lipoproteins</keyword>
	<keyword>metabolic syndrome</keyword>
	<keyword>Rosuvastatin</keyword>
</DOC>